Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Effectiveness of Healthy Lifestyle Intervention on Diabetes Risk Reduction Among Bruneian Young Adults: a Randomised Controlled Trial
Verified date | January 2020 |
Source | Universiti Brunei Darussalam |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The general research question posed was 'How effective is a healthy lifestyle intervention
using behavioural change strategies in the prevention of Type 2 Diabetes Mellitus (T2DM)?'.
The main aim was to assess the effectiveness of a healthy lifestyle intervention implemented
for 12 weeks via face-to-face group sessions and by using social media tools (Facebook and
WhatsApp) for young adults at risk of T2DM.
The hypothesis was that this healthy lifestyle intervention may be effective in terms of
initiating an increased physical activity (PA) level and a healthy balanced dietary intake
resulting in improvements of other T2DM risk factors at 12 weeks.
Status | Completed |
Enrollment | 71 |
Est. completion date | February 27, 2018 |
Est. primary completion date | February 27, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 29 Years |
Eligibility |
Inclusion Criteria: - Bruneian including permanent residents - BMI from 25.00 to 39.99 kg/m2 - American Diabetes Association (ADA) diabetes risk score of at least 3 and maximum score of 8 - Mentally and physically fit with no chronic conditions - Without medical conditions that could influence glucose metabolism and insulin resistance - Answered 'No' to all 6 questions in questionnaire-based pre-exercise risk assessment - Not actively participating in other healthy lifestyle programmes - Had access to computer or mobile phone with Internet |
Country | Name | City | State |
---|---|---|---|
Brunei Darussalam | PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam | Brunei | Bandar Seri Begawan |
Lead Sponsor | Collaborator |
---|---|
Universiti Brunei Darussalam |
Brunei Darussalam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in diabetes risk score from week 0 to week 13 | Using Finnish Diabetes Risk Score (FINDRISC) questionnaire, with minimum score of 0 and maximum score of 22. Score less than 7 as low risk, 7 to 11 as slightly elevated, 12 to 14 as moderate risk, 15 to 20 as high risk and more than 20 as very high risk. | 12 weeks | |
Secondary | Change in weight (kg) | Using digital weighing scale | 12 weeks | |
Secondary | Change in weight (%) | Using digital weighing scale | 12 weeks | |
Secondary | Height in cm | Using digital weighing scale | At baseline | |
Secondary | Change in body mass index (BMI) (kg/m2) | Calculated with weight and height | 12 weeks | |
Secondary | Change in waist circumference (WC) (cm) | Measured at the midpoint between the lower border of the ribcage and iliac crest with tape measure | 12 weeks | |
Secondary | Change in hip circumference (HC) (cm) | Measured at the largest portion of the buttocks with tape measure | 12 weeks | |
Secondary | Change in waist-to-hip ratio (WHR) | Calculated with WC and HC | 12 weeks | |
Secondary | Change in fasting blood glucose (FBG) (mmol/l) | With finger-pricking and AccuTrend Plus System blood analyses | 12 weeks | |
Secondary | Change in fasting blood total cholesterol (TC) (mmol/l) | With finger-pricking and AccuTrend Plus System blood analyses | 12 weeks | |
Secondary | Change in fasting blood triglycerides (TG) (mmol/l) | With finger-pricking and AccuTrend Plus System blood analyses | 12 weeks | |
Secondary | Change in systolic blood pressure (SBP) (mmHg) | Using OMRON automated blood pressure monitor | 12 weeks | |
Secondary | Change in diastolic blood pressure (DBP) (mmHg) | Using OMRON automated blood pressure monitor | 12 weeks | |
Secondary | Change in resting heart rate (pulse/min) | Using OMRON automated blood pressure monitor | 12 weeks | |
Secondary | Change in vigorous PA metabolic task (MET) (min/week) | Using short-form international PA questionnaire (SF-IPAQ) | 12 weeks | |
Secondary | Change in moderate PA MET (min/week) | Using SF-IPAQ | 12 weeks | |
Secondary | Change in walking MET (min/week) | Using SF-IPAQ | 12 weeks | |
Secondary | Change in total PA MET (min/week) | Using SF-IPAQ | 12 weeks | |
Secondary | Change in sitting time (hrs/day) | Using SF-IPAQ | 12 weeks | |
Secondary | Change in intake of carbohydrates (servings/day) | Using 4-day dietary record | 12 weeks | |
Secondary | Change in intake of protein (servings/day) | Using 4-day dietary record | 12 weeks | |
Secondary | Change in intake of fruits (servings/day) | Using 4-day dietary record | 12 weeks | |
Secondary | Change in Intake of vegetables (servings/day) | Using 4-day dietary record | 12 weeks | |
Secondary | Change in intake of water in (litres/day) | Using 4-day dietary record | 12 weeks | |
Secondary | Change in motivation score | Using University of Rhode Island Change Assessment (URICA) with minimum score of -2 and maximum score of 14. The higher the score, the higher the motivation. | 12 weeks | |
Secondary | Change in social support (diet) score | Using social cognitive theory (SCT) constructs scale with minimum score of 1 and maximum score of 4. Higher scores indicate better support for eating healthy. | 12 weeks | |
Secondary | Change in social support (PA) score | Using social cognitive theory (SCT) constructs scale with minimum score of 1 and maximum score of 4. Higher scores indicate better support for exercising | 12 weeks | |
Secondary | Change in overcoming barriers (PA) score | Using social cognitive theory (SCT) constructs scale with minimum score of 1 and maximum score of 4. Higher scores indicate more capabilities to overcome barriers towards exercising | 12 weeks | |
Secondary | Change in moral disengagement (diet) score | Using social cognitive theory (SCT) constructs scale with minimum score of 1 and maximum score of 4. Higher scores indicate lack of control in eating | 12 weeks | |
Secondary | Change in outcome expectations (diet) score | Using social cognitive theory (SCT) constructs scale with minimum score of 1 and maximum score of 4. Higher scores indicate more positive expectations for dieting | 12 weeks | |
Secondary | Change in outcome expectations (PA) score | Using social cognitive theory (SCT) constructs scale with minimum score of 1 and maximum score of 4. Higher scores indicate more positive expectations for exercising | 12 weeks | |
Secondary | Change in emotional coping (PA) score | Using social cognitive theory (SCT) constructs scale with minimum score of 1 and maximum score of 4. Higher scores indicate better emotional coping by exercising | 12 weeks | |
Secondary | Change in self-efficacy (PA) score | Using social cognitive theory (SCT) constructs scale with minimum score of 1 and maximum score of 4. Higher scores indicate better confidence in exercising | 12 weeks | |
Secondary | Facilitation (PA) score | Using social cognitive theory (SCT) constructs scale with minimum score of 1 and maximum score of 4. Higher scores indicate better access to facilities and equipment for exercising | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |